Advanced search
Publication Cover
Experimental Lung Research Volume 28, 2002 - Issue 2
Submit an article Journal homepage
19
Views
7
CrossRef citations to date
0
Altmetric
Research Article

SECRETORY LEUKOCYTE PROTEINASE INHIBITOR AND ELAFIN ARE RESISTANT TO DEGRADATION BY MMP-8

M. T. Henry Department of Medicine and Therapeutics, University College, Dublin, Ireland; [email protected]
,
K. McMahon Department of Medicine and Therapeutics, University College, Dublin, Ireland
,
C. Costello Department of Medicine and Therapeutics, University College, Dublin, Ireland
,
M. X. Fitzgerald Department of Medicine and Therapeutics, University College, Dublin, Ireland
&
C. M. O'Connor Department of Medicine and Therapeutics, University College, Dublin, Ireland
Pages 85-97 | Published online: 02 Jul 2009

  • Stockley R: Proteolytic enzymes, their inhibitors and lung diseases. Clin Sci. 1983;64:119-126.
  • Fujita J, Nelson NL, Daughton DM, Dobry CA, Spurzen JR, Irin o S, Rennard SI: Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am Rev Respir. 1990; 142:57-62.
  • O'Connor CM, Gaffney K, Keane J, Southey A, Byrne N, O'Mahoney S, HtzGerald MX: a- -Proteinase Inhibitor, elastase activity and lung disease severity in cystic fibrosis. Am Rev Respir Dis. 1993;148:1665-1670.
  • Laurell CB, Eriksson EC: The electrophoretic a-l globulin pattern of serum in a-1 antitrypsin deficiency Scand J Clin Lab Invest. 1963;15: 132-140.
  • American Thoracic Society Guidelines for the approach to the patient with severe alpha-1-antitrypsin deficiency Official statement of the ATS. Am Rev Respi Dis. 1989;140:1494-1497.
  • Seersholm N, Wencker M, Banik N, et al: Does alpha 1 antitrypsin augmentation therapy slow the annual decline in FEVi in patients with severe hereditary alpha 1 antitrypsin deficiency. Eur Respir J. 1997:10:2260-2263.
  • Dirksen A, Dijkman JH, Madsen F, et al: A randomised clinical trial of alpha-1-antitrypsin augmentation therapy. Am J Respir Oit Care Med. 1999; 160:1468-1472.
  • Johnson D, Travis J: Structural evidence for methionine at the reactive site for alpha-1-proteinase inhibitor. J Biol Chem. 1979;254:4022-4026.
  • Garke RA, Stone PJ, El Hag A, Galore JD, Franzblau C Myeloperoxidase-catalysed inactivation of a protease inhibitor by human neutrophils. J Biol Chem. 1981;256:3348-3353.
  • Ossanna P, Test S, Matte son N, Regiani S, Wfeiss SJ: Oxidative regulation of neutrophil elastase alpha1-proteinase inhibitor reactions. J Clin Invest. 1986;77:1939-1951.
  • Desrochers PE, Wfeiss SJ: Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase. J Clin Invest. 1988;81:1646-1650.
  • Desrochers PE, Jeffrey JJ, Weiss SJ: Interstitial collagenase (MMP-I) expresses serpinase activity. J Clin Invest 1991;87:2258-2265.
  • Prikk K, Pirila E, Sepper R, Maisi P, et al: In vivo collagenase-2 expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J Pathol. 2001;194:232-238.
  • Woessner JR The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994;732:11-21.
  • Vissers MCM, George PM, Bathurst IC, Brennan SO, Winterbourn CC Cleavage and inactivation of a--Antitrypsin by metalloproteinases released from activated neutrophils. J Clin Invest. 1988;82: 706-711.
  • Sires UI, Murphy G, Baragi VM, et al: Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha-1-antitrypsin. Kochern Biophys Res Commun. 1994;204:613-620.
  • Campbell EJ, Senoir RM, McDonald JA, Cox DL Proteolysis by neutrophils. Relative importance of cell substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest. 1982:70:845-852.
  • Kramps JA, Franken C, Meijer CJ, Dijkman JH: Localisation of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract J Histochem Cytochem. 1981;29:712-719.
  • Sallenave JM, Marsden MD, RyIe AR Isolation of elafin, an elastase specific inhibitor(ESI) from bronchial secretions: evidence of sequence homology and immunological cross reactions. Biol Chem Happe Seyler. 1992;373:27-33.
  • Rice WG, Weiss SJ: Regulation of proteolysis at the neutrophil substrate interface by secretory leucoprotease inhibitor. Science. 1990;249:178-181.
  • McHvaney NG, Doujaiji B, Moan MJ, Burn h am MR, Wu MC, Crystal RG Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis. 1993;148:1056-1660.
  • Bingle L, Tetley TD: Secretory leukoprotease inhibitor partnering al-proteinase inhibitor to combat pulmonary inflammation. Thorax. 1996;51:1273-1274.
  • Vogelmeier C, Gffissen A, Buhl R: Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity Chest. 1996;110(6):261S-266S.
  • Tremblay GM, Sallenave JM, Israël-Assayag E, Cormier X Gauldie J: Elafin/elastase specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am J Respir Grit Care Med. 1996:154:1092-1098.
  • 'Vogelmeier C, Biedermann T, Maier K, et al: Comparative loss of activity of recombinant secretory leukoprotease inhibitor and a--pro tease inhibitor caused by different forms of oxidative stress. Eur Respir j 1997;10:2114-2119.
  • Knauper V, Kramer S, Reinke H, Tschesche H: Characterisation and activation of procollagenase from human polymorphonuclear leucocytes. Bur J Bochem. 1990; 189:295-300.
  • O'Connor CM, Odium CM, Van Breda A, Power C, FitzGerald MX: Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax. 1988;43:393-400.
  • Tsechesche H: Human neutrophil collagenase. Methods Ehzpnol. 1995;248:431-449.
  • Martodam RR, Baugh RJ, Twamasi DX Liener IE A rapid procedure for large scale purification of elastase and cathepsin G from human sputum. Prep Biochem. 1979;9:15-31.
  • Taylor JC, Crawford IR Purification and characterization of human leukocyte elastase. Arch Biochem Biophys. 1975; 169:91-101.
  • McELvaney NG, Hubbard RC Birrer P, Cherniak MS: Aerosol a1-antitrypsin treatment for cystic fibrosis. Lancet. 1991;337:392-394.
  • Snider GL, Lucey EC, Stone Pi Pitfalls in antiprotease therapy of emphysema. Am J Resp Crit Care Med. 1994;150:S131-S137.
  • Llewellyn-Jones CG, Lorn as DA, Stockley RA: Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax. 1994;49:567-572.
  • Vogelmeier C, Hubbard RC, Fells GA, et al: Anti-neutrophil elastase defence of the normal human respiratory epithelium surface provided by secretory Ieukoprotease inhibitor. J Clin Invest. 1991:87:482-488.
  • Boudier C, Bieth JG. Oxidised mucus proteinase inhibitor a fairly potent neutrophil elastase inhibitor. Kochern J. 1994;303:61-68.
  • Stolk J, Camps J, Feitsma HIT, et al: Pulmonary deposition and disappearance of aerosolised secretory leucocyte proteinase inhibitor. Thorax. 1995:50:645-650.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.